TrialRadiation oncology (London, England)2022

MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.

P Hoegen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.